FI890782A - FRIGOERNINGSSYSTEM FOER PHARMACOLOGICAL AEMNEN. - Google Patents

FRIGOERNINGSSYSTEM FOER PHARMACOLOGICAL AEMNEN. Download PDF

Info

Publication number
FI890782A
FI890782A FI890782A FI890782A FI890782A FI 890782 A FI890782 A FI 890782A FI 890782 A FI890782 A FI 890782A FI 890782 A FI890782 A FI 890782A FI 890782 A FI890782 A FI 890782A
Authority
FI
Finland
Prior art keywords
agent
stable
protenoid
microspheres
blood stream
Prior art date
Application number
FI890782A
Other languages
Finnish (fi)
Other versions
FI102456B (en
FI890782A0 (en
FI102456B1 (en
Inventor
Solomon Steiner
Robert Rosen
Original Assignee
Clinical Technologies Ass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1987/002025 external-priority patent/WO1988001213A1/en
Application filed by Clinical Technologies Ass filed Critical Clinical Technologies Ass
Publication of FI890782A publication Critical patent/FI890782A/en
Publication of FI890782A0 publication Critical patent/FI890782A0/en
Application granted granted Critical
Publication of FI102456B publication Critical patent/FI102456B/en
Publication of FI102456B1 publication Critical patent/FI102456B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for targeting the release of an active pharmacological agent in an animal by administering that agent encapsulated in protenoid microspheres, which are stable to the environment encountered from the point of introduction to the targeted body organs, fluids or cells and are there unstable. Orally administered delivery systems for insulin, heparin and physostigmine utilize encapsulating microspheres which are predominantly of less than 10 microns in diameter and pass readily through the stomach wall and which are made of an acidic protenoid that is stable and unaffected by stomach enzymes and acid, but which releases the microencapsulated agent in pharmacologically active form into the near neutral blood stream. Alkaline protenoid microspheres which encapsulate a dopamine redox carrier system are administered in the lower gastrointestinal tract, where they are stable, and then enter the blood stream, where the encapsulated agent is similarly released.
FI890782A 1986-08-18 1989-02-17 Method for microencapsulating pharmacologically active agent in microspheres FI102456B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89736186A 1986-08-18 1986-08-18
US89736186 1986-08-18
US8702025 1987-08-14
PCT/US1987/002025 WO1988001213A1 (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents

Publications (4)

Publication Number Publication Date
FI890782A true FI890782A (en) 1989-02-17
FI890782A0 FI890782A0 (en) 1989-02-17
FI102456B FI102456B (en) 1998-12-15
FI102456B1 FI102456B1 (en) 1998-12-15

Family

ID=25407824

Family Applications (1)

Application Number Title Priority Date Filing Date
FI890782A FI102456B1 (en) 1986-08-18 1989-02-17 Method for microencapsulating pharmacologically active agent in microspheres

Country Status (5)

Country Link
KR (1) KR950009089B1 (en)
CN (1) CN1034858A (en)
DK (1) DK205988A (en)
FI (1) FI102456B1 (en)
HU (1) HU207439B (en)

Also Published As

Publication number Publication date
HU207439B (en) 1993-04-28
FI102456B (en) 1998-12-15
FI890782A0 (en) 1989-02-17
FI102456B1 (en) 1998-12-15
DK205988A (en) 1988-05-31
KR880701601A (en) 1988-11-04
KR950009089B1 (en) 1995-08-14
DK205988D0 (en) 1988-04-15
CN1034858A (en) 1989-08-23
HUT52947A (en) 1990-09-28

Similar Documents

Publication Publication Date Title
GB2217201A (en) Delivery systems for pharmacological agents
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
ATE81287T1 (en) TARGETED ENTERAL DELIVERY SYSTEM.
FI904207A0 (en) FETTSYRA-LAEKEMEDELKONJUGAT FOER TILLFOERING AV LAEKEMEDEL GENOM BLODHJAERNBARRIAEREN.
DE69331906D1 (en) GRANULATED PHARMACEUTICAL COMPOSITION
AR022930A2 (en) RESERVORY TYPE MICROCAPSULES, CONTAINING AT LEAST A MEDICINAL AND / OR NUTRITIVE ACTIVE PRINCIPLE (PA) WITH EXCLUSION OF ACETILSALICILIC ACID (ASA), INTENDED FOR ADMINISTRATION BY ORAL ROUTE, ITS USE AND FORM A PHARMACEUTICAL PURCHASE.
ATE30380T1 (en) MULTIPLE UNIT PHARMACEUTICAL FORMULATIONS.
KR880008803A (en) Spherical granules having a nucleus and a method of manufacturing the same
KR880701543A (en) Microgranular formulations useful for releasing biologically active substances in the long term of animals
SE8602722D0 (en) SUSTAINABLE ADMINISTRATION FORMS
Reddy et al. Colon targeted drug delivery system: a review
PT96921B (en) INTERMITTENT RELEASE DEVICE
FI890782A (en) FRIGOERNINGSSYSTEM FOER PHARMACOLOGICAL AEMNEN.
DK0380950T3 (en) Process for the preparation of a bismuth-based preparation as well as the active product in preparation
SE9601659D0 (en) Diagnostic drug preparation
EP0366058A3 (en) Controlled-release delivery device, method for producing device, and method of using device
Shah et al. DEVELOPMENTS IN COLON SPECIFIC DRUG DELIVERY SYSTEMS-A REVIEW.
Madden et al. Some unusual aspects of microsphere migration at the microcirculatory level
DE3688355D1 (en) SOLID BODY WITH COVERED CORE.
SHETTY et al. INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Keerthi INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: EMISPHERE TECHNOLOGIES, INC.